(1137-101) A Phase I Trial of CBL0137 in Patients with Advanced Solid Neoplasms
The primary objective of the study is to determine the maximally tolerated dose and recommended Phase 2 dose of CBL0137 when administered intravenously to patients with metastatic or unresectable advanced solid malignancies or refractory lymphomas.
Study Number: 

I 235913

Early Phase
Principal Investigator: 
ClinicalTrials.Gov ID: 

To inquire about participating in these studies, call 1-877-ASK-RPCI (1-877-275-7724) or e-mail askrpci@roswellpark.org.